Latest Breaking News On - Carefirst of md inc - Page 1 : vimarsana.com

While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.

Virginia
United-states
Maryland
Andrey-popov
Fresenius-kabi
Johnson
Lowey-dannenberg
Samsung-bioepis
Carefirst-bluecross-blueshield
Trademark-office
Us-district-court
Carefirst-of-md-inc